Claim OwnershipLiving Rheum
Subscribed: 11Played: 20
Subscribe
© Copyright 2026 ReachMD. All rights reserved.
Description
Dedicated to uncovering clinical developments and treatment advancements in the field of rheumatology, Living Rheum delivers expert insights on patient management across a broad spectrum of rheumatic diseases, such as rheumatoid arthritis, lupus, scleroderma, osteoporosis, and more.
42 Episodes
Reverse
Guest: Laura Coates, MBChB, MRCP, PhD
As our understanding of psoriatic arthritis deepens, we're starting to turn our attention toward intervention: preventing the disease before it progresses or is officially diagnosed. Tune in to hear Dr. Laura Coates discuss the evolving landscape of psoriatic arthritis prevention and interception, including the challenges and opportunities in identifying at-risk patients and designing effective early intervention studies. Dr. Coates is an NIHR Research Professor and Senior Clinical Research Fellow at the University of Oxford in the United Kingdom.
Guest: Laura Coates, MBChB, MRCP, PhD
Can treating psoriasis early with biologics help prevent psoriatic arthritis? The data’s promising—but it’s complicated. Join Dr. Laura Coates as she unpacks the latest research, explaining how early intervention may influence outcomes and what real-world challenges come with interpreting observational data. Dr. Coates is an NIHR Research Professor and Senior Clinical Research Fellow at the University of Oxford in the United Kingdom.
Guest: Laura Coates, MBChB, MRCP, PhD
Managing psoriatic arthritis gets more complex when patients don’t respond to standard treatments or present with overlapping conditions. Hear Dr. Laura Coates' insights on difficult-to-treat and complex-to-manage psoriatic arthritis—highlighting how clear classification can guide more targeted therapies, research, and support strategies for these often-overlooked patient populations. Dr. Coates is an NIHR Research Professor and Senior Clinical Research Fellow at the University of Oxford in the United Kingdom.
Host: Flavia Castelino, MD
Guest: Benjamin Korman, MD
Systemic sclerosis (SSc) is complex and often diagnosed late. Explore the vasculopathy-fibrosis axis as a key driver of disease progression and clinical manifestations. Learn to recognize phenotypic red flags for ILD, PAH, and renal crisis, and apply risk stratification strategies to guide earlier intervention. Check out the evolving evidence on treatment selection and serious complications, emphasizing multidisciplinary care models and the role of patient-reported outcomes.
Host: Steve Jackson, PharmD
Guest: Marc Scherlinger, MD, PhD
Systemic lupus erythematosus (SLE) treatment is undergoing a transformative shift from broad immunosuppression to targeted, precision-based approaches. Dr. Marc Scherlinger joins Dr. Steve Jackson to provide a timely update on recent breakthroughs, including monoclonal antibodies, JAK and BTK inhibitors, and CAR T-cell therapies, as well as challenges in translating novel therapies into clinical practice. Dr. Scherlinger is a Clinical Chief at the Strasbourg University Hospital in France.
Host: Ryan Quigley
Guest: Luigi Adamo, MD, PhD
Guest: Andrea Fava, MD
Fatigue and exercise intolerance in patients with systemic lupus erythematosus (SLE) may persist even when disease activity is controlled, and preload deficiency could be an overlooked cause. In this expert-led discussion, Drs. Luigi Adamo and Andrea Fava share insights from their research, highlighting diagnostic clues, the role of NT-proBNP, and emerging interventions aimed at improving quality of life. Dr. Adamo is an Associate Professor of Medicine and the Director of Cardiac Immunology, and Dr. Fava is an Assistant Professor of Medicine in the Division of Rheumatology and Director of Lupus Translational Research at Johns Hopkins Medicine.
Guest: Gary S. Firestein, MD
Despite advances in biologics, many patients with rheumatoid arthritis still experience persistent inflammation. However, cadherin-6 has recently been identified as a potential treatment target. Hear from Dr. Gary Firestein as he explains the discovery, function, and therapeutic potential of cadherin-6 in rheumatoid arthritis pathogenesis. Dr. Firestein is a Distinguished Professor of Medicine and the Senior Associate Vice Chancellor for Health Sciences at UC San Diego.
Guest: Gary S. Firestein, MD
While cadherin-6 may not yet shift clinical practice in rheumatoid arthritis, its role as a surface-expressed, actionable target opens the door to rapid therapeutic development—particularly with existing antibodies already in clinical trials for urologic cancers. Dr. Gary Firestein discusses the potential for cadherin-6 to become a useful target across multiple diseases. Dr. Firestein is a Distinguished Professor of Medicine and the Senior Associate Vice Chancellor for Health Sciences at UC San Diego.
Host: Ryan Quigley
New research presented at the 2025 American College of Rheumatology Convergence highlights a critical link between adverse childhood experiences and mental health outcomes in adolescents with childhood-onset systemic lupus erythematosus (cSLE). In this AudioAbstract, Ryan Quigley explores the findings, the implications for trauma-informed care, and the need to assess psychosocial history in managing cSLE.
Guest: Leonard Calabrese, DO
Preventing serious infections should be a priority when treating patients with immune-mediated inflammatory diseases, especially those receiving immunosuppressive therapies. By assessing patients’ level of immunocompetence, clinicians can better tailor vaccination strategies and optimize infection prevention. Hear Dr. Leonard Calabrese discuss how to evaluate immunosuppression risk and coordinate timely vaccinations for patients undergoing immunomodulatory treatments. Dr. Calabrese heads the Section of Clinical Immunology at the Cleveland Clinic in Ohio, where he manages the Clinical Immunology Clinic and is on the staff of the Department of Rheumatic and Immunologic Diseases. He also spoke on this topic at the 2025 Congress of Clinical Rheumatology West conference.
Guest: Joan Merill, MD
Despite common misconceptions, lupus nephritis is part of a broader immune imbalance seen in systemic lupus, not a separate condition. This is why it's important to shift focus from organ-specific treatment to immune dysregulation targeting. Hear Dr. Joan Merrill, Professor at the Oklahoma Medical Research Foundation’s Arthritis and Clinical Immunology Research Program in Oklahoma City, discuss the spectrum of lupus and, based on that, considerations for treatment. Dr. Merrill also presented on this topic at the 2025 Congress of Clinical Rheumatology West conference.
Guest: Martin Cheatle, PhD
Chronic pain is now recognized as a distinct disease that requires more than just a symptom-based approach. Lifestyle factors and psychological health are also important considerations for care, which is why a biopsychosocial approach can be key to better outcomes. Hear Dr. Martin Cheatle discuss the importance of this clinical mindset shift and practical strategies to help patients reduce suffering and improve function. Dr. Cheatle is an Associate Professor of Anesthesiology at the Hospital of the University of Pennsylvania and serves as Director of Behavioral Medicine at the PENN Pain Medicine Center and Director of Pain and Chemical Dependency Research at the Center for Studies of Addiction. He also gave a presentation on this topic at the 2025 Congress of Clinical Rheumatology West conference.
Diagnosing long COVID continues to pose challenges for clinicians and patients alike. While 2024 diagnostic criteria from the National Academies aimed to make navigating it easier, the framework may raise some concerns, particularly for rheumatologists. Hear Ryan Quigley break down a commentary on the criteria published in July 2025 in Arthritis & Rheumatology that outlines why it may cause problems in the rheumatology community.
Guest: Martin Cheatle, PhD
A thoughtful, communicative, and compassionate approach to opioid use is essential for responsible patient use. Join Dr. Martin Cheatle as he explains the neuroscience of chronic pain, the psychosocial components often overlooked in these patients, and evidence-based strategies for evaluating risk and treatment response. Dr. Cheatle is the Director of Behavioral Medicine at the Penn Pain Medicine Center as well as an Associate Professor of Psychiatry, Anesthesiology, and Critical Care and the Director of Pain and Chemical Dependency Research at the Center for Studies of Addiction at the University of Pennsylvania. He also presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Michelle Kahlenberg, MD, PhD
Lupus arises from a complex interaction of genetics, environmental stimuli, and immune system errors. Dive into the pathophysiology behind the disease with Dr. Michelle Kahlenberg, the Giles Boles and Dorothy Mulkey Research Professor of Rheumatology and Professor of Internal Medicine and Dermatology at the University of Michigan, as she examines the mechanisms that contribute to the development of autoreactive immune responses. Dr. Kahlenberg also spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: John Bridges, MD, MS
For children with rheumatic diseases, early diagnosis, personalized care, and multidisciplinary collaboration are critical for optimal long-term management. Join Dr. John Bridges, Assistant Professor in the Division of Pediatric Rheumatology at the University of Alabama at Birmingham Heersink School of Medicine, as he explains how access, timing, and collaboration shape pediatric rheumatology care. Dr. Bridges presented on this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Laura Cappelli, MD, MHS,MS
Patients who are receiving immunotherapy for cancer sometimes develop significant autoimmune complications, which can be fatal. Join Dr. Laura Cappelli, Associate Professor of Medicine and Oncology at the Johns Hopkins University School of Medicine, as she explains how multidisciplinary collaboration can help manage these rheumatic immune-related adverse events (irAEs). Dr. Cappelli also spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Michelle Kahlenberg, MD, PhD
Our approach to lupus management is accelerating, with emerging results on targeted therapies in skin and renal disease showing promise. Dr. Michelle Kahlenberg shares insights on emerging biologics, CAR-T innovations, and potential barriers in translating treatment breakthroughs into real-world patient care. Dr. Kahlenberg is the Giles Boles and Dorothy Mulkey Research Professor of Rheumatology and a Professor of Internal Medicine at Dermatology at the University of Michigan, and she spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.
Guest: Robin Dore, MD
Rheumatoid arthritis presents uniquely in every patient, which can make treatment decisions complex. As a result, it’s important to balance factors like symptom variations, patient concerns, and medical guidelines to find the right approach. Hear how risk-benefit discussions and evolving treatment strategies can shape care from Dr. Robin Dore, a board-certified rheumatologist and an Invited Lecturer at the University of California, Irvine in the Division of Rheumatology.
Guest: Robin Dore, MD
Despite the challenges of managing rheumatoid arthritis—especially for patients with difficult-to-treat cases or a history of cancer—clinical trials, updated guidelines, and data-driven decision-making are helping to shape the future of care. Dive deeper into how rheumatoid arthritis treatment is evolving with Dr. Robin Dore, board-certified rheumatologist and Invited Lecturer at the University of California, Irvine in the Division of Rheumatology.
Comments
Download from Google Play
Download from App Store
United States